CMTR1 is associated with increased asthma exacerbations in patients taking inhaled corticosteroids

Immunity Inflammation and Disease

Volumn 3, Issue 4, 2015, Pages 350-359

  Dahlin, Amber ^a   Denny, Joshua ^b,c   Roden, Dan M ^b   Brilliant, Murray H ^d   Ingram, Christie ^c   Kitchner, Terrie E ^d   Linneman, James G ^d   Shaffer, Christian M ^c   Weeke, Peter ^c,e   Xu, Hua ^f   Kubo, Michiaki ^g   Tamari, Mayumi ^g   Clemmer, George L ^a   Ziniti, John ^a   McGeachie, Michael J ^a   Tantisira, Kelan G ^a   Weiss, Scott T ^a   Wu, Ann Chen ^a,h  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d MARSHFIELD CLINIC   (United States)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF TEXAS   (United States)

^g RIKEN   (Japan)

^h HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Asthma; EMR; Exacerbations; GWAS; Inhaled corticosteroids; Pharmacogenomics

Indexed keywords

EID: 84962112759     PISSN: None     EISSN: 20504527     Source Type: Journal    
DOI: 10.1002/iid3.73     Document Type: Article

References (47)

1. (GINA). GIfA. Global strategy for asthma management and prevention: Update 2012. 2012.
2. (NAEPP). NAEaPP. Expert panel Report 3: Guidelines for the diagnosis and management of asthma [Publication 08-405]. Bethesda, MD: National Institutes of Health; 2007.
3. Jarjour, N. N., S. C. Erzurum, E. R. Bleecker, W. J. Calhoun, M. Castro, S. A. Comhair, K. F. Chung, D. Curran-Everett, R. A. Dweik, S. B. Fain, et al. 2012. Severe asthma: lessons learned from the national heart, lung, and blood institute severe asthma research program. Am. J. Respir. Crit. Care. Med. 185(4):356–362.
4. Bahadori, K., M. M. Doyle-Waters, C. Marra, L. Lynd, K. Alasaly, J. Swiston, J. M. FitzGerald. 2009. Economic burden of asthma: a systematic review. BMC Pulm. Med. 9:24.
5. Chan, M. T., D. Y. Leung, S. J. Szefler, and J. D. Spahn. 1998. Difficult-to-control asthma: clinical characteristics of ste-roid-insensitive asthma. J. Allergy Clin. Immunol. 101-(5):594–601.
6. 1 change by corticosteroid. Clin. Chim. Acta. 436:20–26.
7. Park, H. W., A. Dahlin, S. Tse, Q. L. Duan, B. Schuemann, F. D. Martinez, S. P. Peters, S. J. Szefler, J. J. Lima, M. Kubo, et al. 2014. Genetic predictors associated with improvement of asthma symptoms in response to inhaled corticosteroids. J. Allergy Clin. Immunol. 133(3):664–669.
8. Konno, S., N. Hizawa, H. Makita, K. Shimizu, T. Sakamoto, F. Kokubu, T. Saito, T. Endo, H. Ninomiya, H. Iijima, et al. 2014. The effects of a Gly16Arg ADRB2 polymorphism on responses to salmeterol or montelukast in Japanese patients with mild persistent asthma. Pharmacogenet. Genomics. 24(5):246–255.
9. Izuhara, Y., H. Matsumoto, Y. Kanemitsu, K. Izuhara, Y. Tohda, T. Horiguchi, H. Kita, K. Kuwabara, K. Tomii, K. Otsuka, et al. 2014. GLCCI1 variant accelerates pulmonary function decline in patients with asthma receiving inhaled corticosteroids. Allergy. 69(5):668–673.
10. Zuurhout, M. J., S. J. Vijverberg, J. A. Raaijmakers, K. Izuhara, Y. Tohda, T. Horiguchi, H. Kita, K. Kuwabara, K. Tomii, K. Otsuka, et al. 2013. Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting b2-agonists: results of the PACMAN cohort. Pharmacogenomics. 14(16):1965–1971.
11. Berce, V., C. E. Kozmus, and U. Potočnik. 2013. Association among ORMDL3 gene expression, 17q21 polymorphism and response to treatment with inhaled corticosteroids in children with asthma. Pharmacogenomics J. 13(6):523–529.
12. Iordanidou, M., E. Paraskakis, A. Tavridou, P. Paschou, A. Chatzimichael, and V. G. Manolopoulos. 2012. G894T polymorphism of eNOS gene is a predictor of response to combination of inhaled corticosteroids with long-lasting b2-agonists in asthmatic children. Pharmacogenomics 13-(12):1363–1372.
13. McGeachie, M. J., A. C. Wu, H. H. Chang, J. J. Lima, S. P. Peters, and K. G. Tantisira. 2013. Predicting inhaled corticosteroid response in asthma with two associated SNPs. Pharmacogenomics J. 13(4):306–311.
14. Ambrose, H. J., R. M. Lawrance, C. J. Cresswell, M. Goldman, D. A. Meyers, and E. R. Bleecker. 2012. Effect of b2-adrenergic receptor gene (ADRB2) 3’ untranslated region polymorphisms on inhaled corticosteroid/long-acting b2-adrenergic agonist response. Respir Res. 13:37.
15. Balantic, M., M. Rijavec, M. Skerbinjek Kavalar, S. Suskovic, M. Silar, M. Kosnik, and P. Korosec. 2012. Asthma treatment outcome in children is associated with vascular endothelial growth factor A (VEGFA) polymorphisms. Mol. Diagn. Ther. 16(3):173–180.
16. Dijkstra, A., D. S. Postma, M. Bruinenberg, C. C. van Diemen, H. M. Boezen, G. H. Koppelman, W. Timens, and J. M. Vonk. 2011. SERPINE 1–675 4G/5G polymorphism is associated with asthma severity and inhaled corticosteroid response. Eur. Respir. J. 38(5):1036–1043.
17. Ò , et al. 2011. ADRB2 Gly16Arg polymorphism, asthma control and lung function decline. Eur. Respir. J. 38-(5):1029–1035.
18. Jin, Y., D. Hu, E. L. Peterson, A. M. Levin, K. Wells, K. Beckman, R. Kumar, M. A. Seibold, G. Karungi, et al. 2010. Dual-specificity phosphatase 1 as a pharmacogenetic modifier of inhaled steroid response among asthmatic patients. J. Allergy Clin. Immunol. 126(3):618–625 e611–612.
19. Ye, Y. M., H. Y. Lee, S. H. Kim, Y. K. Jee, S. K. Lee, S. H. Lee, and H. S. Park. 2009. Pharmacogenetic study of the effects of NK2R G231E G>A and TBX21 H33Q C>G polymorphisms on asthma control with inhaled corticosteroid treatment. J. Clin. Pharm. Ther. 34(6):693–701.
20. Kopriva, F., P. Dzubak, J. Potesil, and M. Hajduch. 2009. The anti-inflammatory effects of inhaled corticosteroids versus anti-leukotrienes on the lymphocyte P-glycoprotein (PGP) expression in asthmatic children. J. Asthma. 46-(4):366–370.
21. Tantisira, K. G., E. S. Silverman, T. J. Mariani, J. Xu, B. G. Richter, B. J. Klanderman, A. A. Litonjua, R. Lazarus, L. J. Rosenwasser, A. L. Fuhlbrigge, et al. 2007. FCE R2: a pharmacogenetic basis for severe exacerbations in children with asthma. J. Allergy Clin. Immunol. 120(6):1285–1291.
22. Tantisira, K. G., J. Lasky-Su, M. Harada, A. Murphy, A. A. Litonjua, B. E. Himes, C. Lange, R. Lazarus, J. Sylvia, B. Klanderman, et al. 2011. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N. Engl. J. Med. 365(13):1173–1183.
23. Chiappara, G., P. Chanez, A. Bruno, E. Pace, F. Pompeo, J. Bousquet, G. Bonsignore, and M. Gjomarkaj. 2007. Variable p-CREB expression depicts different asthma phenotypes. Allergy 62(7):787–794.
24. Vijverberg, S. J., E. S. Koster, R. Tavendale, M. Leusink, L. Koenderman, J. A. Raaijmakers, D. S. Postma, G. H. Koppelman, S. W. Turner, S. Mukhopadhyay, et al. 2015. ST13 polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults. Clin Exp Allergy 45(6):1051–1059.
25. Bleecker, E. R., D. S. Postma, R. M. Lawrance, D. A. Meyers, H. J. Ambrose, and M. Goldman. 2007. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 370(9605):2118–2125.
26. Denlinger, L. C., D. M. Manthei, M. A. Seibold, K. Ahn, E. Bleecker, H. A. Boushey, W. J. Calhoun, M. Castro, V. M. Chinchili, J. V. Fahy, et al. 2013. P2x7-regulated protection from exacerbations and loss of control is independent of asthma maintenance therapy. Am. J. Respir. Crit. Care Med. 187(1):28–33.
27. Koster, E. S., A. H. Maitland-van der Zee, R. Tavendale, S. Mukhopadhyay, S. J. Vijverberg, J. A. Raaijmakers, and C. N. Palmer. 2011. FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid-treated asthmatic children. Allergy 66(12):1546–1552.
28. Hunninghake, G. M., M. E. Soto-Quirós, L. Avila, J. Su, A. Murphy, D. L. Demeo, N. P. Ly, C. Liang, J. S. Sylvia, B. J. Klanderman, et al. 2007. Polymorphisms in IL13, total IgE, eosinophilia, and asthma exacerbations in childhood. J. Allergy Clin. Immunol. 120(1):84–90.
29. Roden, D. M., J. M. Pulley, M. A. Basford, G. R. Bernard, E. W. Clayton, J. R. Balser, and D. R. Masys. 2008. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin. Pharmacol. Ther. 84-(3):362–369.
30. Wilke, R. A., R. L. Berg, P. Peissig, T. Kitchner, B. Sijercic, C. A. McCarty, and D. J. McCarty. 2007. Use of an electronic medical record for the identification of research subjects with diabetes mellitus. Clin. Med. Res. 5(1):1–7.
31. Ritchie, M. D., J. C. Denny, D. C. Crawford, A. H. Ramirez, J. B. Weiner, J. M. Pulley, M. A. Basford, K. Brown-Gentry, J. R. Balser, D. R. Masys, et al. 2010. Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. Am. J. Hum. Genet. 86-(4):560–572.
32. Purcell, S., B. Neale, K. Todd-Brown, L. Thomas, M. A. Ferreira, D. Bender, J. Maller, P. Sklar, P. I. de Bakker, M. J. Daly, et al. 2007. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81(3):559–575.
33. Chen, W. M., and G. R. Abecasis. 2007. Family-based association tests for genomewide association scans. Am. J. Hum Genet. 81(5):913–926.
34. Liptak, T. 1958. On the combination of independent tests. Magyar Tud. Akad. Mat. Kutato Int. Kozl. 3:171–197.
35. Bosco, A., S. Ehteshami, S. Panyala, and F. D. Martinez. 2012. Interferon regulatory factor 7 is a major hub connecting interferon-mediated responses in virus-induced asthma exacerbations in vivo. J. Allergy Clin. Immunol. 129(1):88–94.
36. Smyth G. K. 2005. Limma: linear models for microarray data. Pp. 397–420 in R G, V C, S D, R I, W H, eds. Bioinformatics and computational biology solutions using R and biocon-ductor. New York: Springer.
37. Johnston, N. W., and M. R. Sears. 2006. Asthma exacerbations. 1: epidemiology. Thorax 61(8):722–728.
38. Jackson, D. J., A. Sykes, P. Mallia, and S. L. Johnston. 2011. Asthma exacerbations: origin, effect, and prevention. J. Allergy Clin. Immunol. 128(6):1165–1174.
39. é langer, F., J. Stepinski, E. Darzynkiewicz, and J. Pelletier. 2010. Characterization of hMTr1, a human Cap1 2’-O-ribose methyltransferase. J. Biol. Chem. 285(43):33037–33044.
40. Shuman, S. 2002. What messenger RNA capping tells us about eukaryotic evolution. Nat. Rev. Mol. Cell Biol. 3(8):619–625.
41. Gu, M., and C. D. Lima. 2005. Processing the message: structural insights into capping and decapping mRNA. Curr. Opin. Struct. Biol. 15(1):99–106.
42. Züst, R., L. Cervantes-Barragan, M. Habjan, R. Maier, B. W. Neuman, J. Ziebuhr, K. J. Szretter, S. C. Baker, W. Barchet, M. S. Diamond, et al. 2011. Ribose 2’-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat. Immunol. 12(2):137–143.
43. Haline-Vaz, T., T. C. Silva, and N. I. Zanchin. 2008. The human interferon-regulated ISG95 protein interacts with RNA polymerase II and shows methyltransferase activity. Biochem Biophys Res Commun. 372(4):719–724.
44. Kato, A., T. Homma, J. Batchelor, N. Hashimoto, S. Imai, H. Wakiguchi, H. Saito, and K. Matsumoto. 2003. Interferon-alpha/beta receptor-mediated selective induction of a gene cluster by CpG oligodeoxynucleotide 2006. BMC Immunol. 4:8.
45. Tan, W. C. 2005. Viruses in asthma exacerbations. Curr. Opin. Pulm. Med. 11(1):21–26.
46. Dijkstra, A. E., D. S. Postma, B. van Ginneken, M. O. Wielp€utz, M. Schmidt, N. Becker, M. Owsijewitsch, H. U. Kauczor, H. J. de Koning, J. W. Lammers, et al. 2015. Novel genes for airway wall thickness identified with combined genome-wide association and expression analyses. Am. J. Respir. Crit. Care Med. 191(5):547–556.
47. Freĭdin, M. B., EIu. Bragina, O. S. Fedorova, I. A. Deev, E. S. Kulikov, L. M. Ogorodova, and V. P. Puzyrev. 2011. Genomewide association study of allergic diseases in Russians of Western Siberia. Mol Biol (Mosk) 45(3):464–472.